R

Rhythm Pharmaceuticals
D

RYTM

56.090
USD
-1.66
(-2.87%)
مغلق
حجم التداول
12,089
الربح لكل سهم
-3
العائد الربحي
-
P/E
-13
حجم السوق
3,447,127,000
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARWR
    -1.040
    (-4.97%)
    19.900 USD
    C
    CRBP
    -0.09000
    (-1.09%)
    8.20000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    P
    PRQR
    -0.02000
    (-0.77%)
    2.57000 USD
    Q
    QURE
    -0.130
    (-1.00%)
    12.840 USD
    R
    RARE
    -1.920
    (-4.31%)
    42.590 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    المزيد
الأخبار
المقالات

العنوان: Rhythm Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.